Cardiology – Page 8

Cardiac Myosin Activation Across the Lifespan: Age-Based Efficacy and Safety of Omecamtiv Mecarbil in HFrEF

By MedXY 12/28/2025

This review synthesizes findings from the GALACTIC-HF trial regarding the efficacy and safety of omecamtiv mecarbil across age groups, highlighting its benefits in older patients and those with severe heart failure.

Cardiology Critical Care news

Beyond Chronological Age: How Frailty Dictates Survival and Functional Recovery After Out-of-Hospital Cardiac Arrest

By MedXY 12/28/2025

A secondary analysis of the TTM2 trial reveals that frailty is a potent predictor of mortality and poor neurological outcomes after out-of-hospital cardiac arrest, with severely frail patients facing a 35-fold higher risk of poor functional recovery.

Cardiology news Public Health

Comprehensive Review of Digital Nudges to Enhance Influenza Vaccination Uptake in Chronic and Cardiovascular Disease Patients

By MedXY 12/28/2025

Electronic behavioral nudges significantly improve influenza vaccination rates among patients with chronic and cardiovascular diseases, offering scalable public health strategies.

Cardiology Clinical Updates news

Repurposing Hydroxychloroquine for Chronic Inflammatory Cardiomyopathy: Evidence from the HYPIC Multicenter Randomized Trial

By MedXY 12/28/2025

The HYPIC trial demonstrates that hydroxychloroquine combined with prednisolone significantly improves cardiovascular outcomes, cardiac function, and cytokine profiles in patients with chronic inflammatory cardiomyopathy following fulminant myocarditis, establishing a novel evidence-based therapeutic strategy.

Cardiology news

A Universal Threshold? High-Sensitivity Troponin I Emerges as a Robust Prognostic Tool in Wild-Type Transthyretin Amyloid Cardiomyopathy

By MedXY 12/27/2025

A multicenter study identifies 80 ng/L as a critical hs-cTnI threshold for mortality risk in wild-type transthyretin amyloid cardiomyopathy, offering a standardized approach for staging and prognosis across various diagnostic assays.

Cardiology Internal Medicine news

Redefining Iron Deficiency in Heart Failure: Why TSAT and Serum Iron Outperform Ferritin for Prognosis

By MedXY 12/26/2025

Recent large-scale studies, including HEART-FID and major national registries, demonstrate that transferrin saturation (TSAT) and serum iron levels are more accurate predictors of functional capacity and mortality in heart failure than traditional ferritin-based definitions.

Cardiology Family Medicine & Nutrition news

Beyond Sodium Restriction: Legumes and Vegetables Linked to Improved Outcomes in Heart Failure

By MedXY 12/26/2025

A substudy of the global G-CHF registry demonstrates that higher intake of legumes and vegetables significantly reduces the risk of death and hospitalization in heart failure patients, while refined grains increase risk, highlighting the importance of food quality over simple nutrient restriction.

Cardiology Nephrology news

Empagliflozin Enhances Cardiovascular Protection in HFrEF Patients with Low Serum Magnesium: Evidence from EMPEROR-Reduced

By MedXY 12/26/2025

This analysis of the EMPEROR-Reduced trial demonstrates that empagliflozin increases serum magnesium levels and provides a more pronounced reduction in cardiovascular events for patients with low baseline magnesium, revealing a novel electrolyte-stabilizing benefit of SGLT2 inhibitors.

Cardiology news

PDE9 Inhibition with CRD-740 Safely Elevates cGMP Levels in HFrEF: Results from the CARDINAL-HF Trial

By MedXY 12/26/2025

The Phase 2 CARDINAL-HF trial demonstrates that CRD-740, a novel PDE9 inhibitor, significantly increases plasma and urinary cGMP in patients with heart failure and reduced ejection fraction. The treatment was well tolerated and effective even alongside sacubitril/valsartan, suggesting a potential new therapeutic pathway.

Cardiology Diabetes & Endocrinology news

Elevated Natriuretic Peptides: A Potent Predictor of Heart Failure and Mortality in Asymptomatic Diabetes

By MedXY 12/26/2025

A large-scale cohort study demonstrates that screening natriuretic peptide levels in individuals with type 1 or type 2 diabetes significantly predicts incident heart failure and death, advocating for routine biomarker-based risk stratification in this high-risk population.

Cardiology Internal Medicine news

Beyond the Scale: Abdominal Adiposity Outperforms BMI in Predicting Outcomes for HFpEF and HFmrEF

By MedXY 12/26/2025

A pooled analysis of 21,479 HFpEF/HFmrEF patients reveals that waist-to-height ratio is a superior, linear predictor of mortality and heart failure events compared to BMI. Even in non-obese BMI categories, nearly 90% of patients exhibit excess abdominal adiposity, necessitating a shift in clinical assessment.

Cardiology Internal Medicine news

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF

By MedXY 12/26/2025

A pooled analysis of 14,750 patients reveals that current fixed NT-proBNP thresholds significantly underestimate cardiovascular risk in obese patients with heart failure, suggesting a critical need for BMI-adjusted diagnostic and trial eligibility cutoffs.

Cardiology Diabetes & Endocrinology news

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP

By MedXY 12/26/2025

A post-hoc analysis of the Look AHEAD trial demonstrates that NT-proBNP levels can identify patients with type 2 diabetes who benefit most from intensive lifestyle interventions. ILI significantly reduced HFpEF risk in those with elevated or stable/decreasing NT-proBNP, supporting a biomarker-guided approach to prevention.

Cardiology news Pediatrics

Cardiac Progenitor Cells in Hypoplastic Left Heart Syndrome: Safety Established, but Efficacy Remains Elusive in the CHILD Trial

By MedXY 12/26/2025

The Phase I CHILD trial demonstrates that intramyocardial injection of neonatal cardiac progenitor cells during HLHS palliation is safe but does not improve right ventricular function at one year, despite promising signals in secondary clinical outcomes.

Cardiology Clinical Updates news

Finerenone in the Management of HFmrEF and HFpEF: A Comprehensive Synthesis of Evidence from the FINEARTS-HF Trial

By MedXY 12/26/2025

This clinical review synthesizes data from the FINEARTS-HF trial, highlighting finerenone's efficacy in reducing heart failure events and cardiovascular mortality across diverse patient profiles, including those with frailty, obesity, and chronic obstructive pulmonary disease.

Cardiology news

Finerenone and Hypotension Risk in Heart Failure: Evidence from the FINEARTS-HF Trial

By MedXY 12/26/2025

This analysis of the FINEARTS-HF trial identifies that while finerenone increases hypotension risk in HFmrEF and HFpEF patients, its clinical benefits persist. The study highlights key predictors of hypotension, such as low baseline blood pressure and advanced age, emphasizing the need for vigilant clinical monitoring.

Cardiology news

Nanosecond Pulsed Field Ablation Matches Radiofrequency Efficacy While Slashing Procedure Time: Insights From the InsightPFA Trial

By MedXY 12/26/2025

The InsightPFA trial confirms that a novel nanosecond pulsed field ablation (nsPFA) system is noninferior to radiofrequency ablation for paroxysmal atrial fibrillation, significantly reducing procedure and left atrial dwell times while maintaining a comparable safety profile.

Cardiology news

Beyond Beta-Blockers: Aficamten Reinvents First-Line Therapy for Obstructive Hypertrophic Cardiomyopathy

By MedXY 12/25/2025

The MAPLE-HCM trial demonstrates that aficamten monotherapy provides superior, rapid, and comprehensive clinical benefits compared to the traditional first-line treatment, metoprolol, across multiple disease domains in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Cardiology Clinical Updates news

Comparative Efficacy, Safety, and Complications of Subcutaneous Versus Transvenous Implantable Cardioverter-Defibrillators: Insights from the PRAETORIAN and ATLAS Trials and Meta-Analyses

By MedXY 12/25/2025

This review synthesizes randomized trial data comparing subcutaneous and transvenous ICDs, highlighting differences in inappropriate shocks, device-related complications, and shock efficacy, underscoring clinical considerations for ICD selection.

Cardiology Internal Medicine news

High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD

By MedXY 12/25/2025

A prespecified analysis of the FOURIER trial reveals that patients with obesity and atherosclerotic cardiovascular disease experience significantly higher absolute and relative risk reductions with evolocumab, particularly those with a BMI above 35 kg/m2, emphasizing a targeted therapeutic advantage for this high-risk population.